Variable | Cardiomyopathy (N = 190) | Masses (N = 13) | Myocarditis (N = 18) | Valves (N = 19) | P-value |
Management changed | 167 (87.9%) | 11 (84.6%) | 16 (88.9%) | 17 (89.5%) | 0.971 (F) |
Added medications | 28 (14.7%) | 1 (7.7%) | 7 (38.9%) | 1 (5.3%) | 0.036 (F)* |
Discontinued medications | 25 (13.2%) | 4 (30.8%) | 3 (16.7%) | 0 (0.0%) | 0.065 (F) |
Led to intervention | 49 (25.8%) | 2 (15.4%) | 2 (11.1%) | 7 (36.8%) | 0.283 (F) |
Obviated intervention | 46 (24.2%) | 2 (15.4%) | 0 (0.0%) | 2 (10.5%) | 0.041 (F)* |
Additional testing | 46 (24.2%) | 3 (23.1%) | 7 (38.9%) | 4 (21.1%) | 0.580 (F) |
Canceled testing | 39 (20.5%) | 2 (15.4%) | 2 (11.1%) | 2 (10.5%) | 0.698 (F) |